The Missed Vital Sign

The Missed Vital Sign is a $50M Wellcome Leap program in women's health centered on heavy menstrual bleeding. Wellcome Leap frames the condition as one that affects about one in three women and can remain untreated for far too long before effective care begins. The program is active, but its solicitation is closed and the selected performers are already in execution. Its work is organized around three thrust areas: earlier identification, better diagnostics, and non-hormonal treatment options. The stated goal is to shorten the average time from onset to effective treatment from five years to five months. Thirteen institutions and researchers have already been selected, and the public record gives no open RFP route for new applicants. That makes the program a fit for teams that can execute against a defined clinical problem rather than shape the agenda from scratch. The emphasis is on diagnosis and treatment pathways that can change how heavy menstrual bleeding is recognized and managed in practice. In public-facing terms, the program is already past selection and into delivery.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.